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planning purposes, a 1.5T MRI was made directly after US 
guided catheter placement. Two sets of 3D MR images were 
acquired using balanced steady state free precession 
sequences with fat suppression; SPIR (spectral presaturation 
with inversion recovery) in sagittal and SPAIR (spectral 
attenuated inversion recovery) in transverse direction. These 
planning scans were used for catheter reconstruction and 
generation of the intra-operative HDR brachytherapy plan 
(Figure 1a,b). After treatment (before removal of catheters), 
a second MRI was performed. Regions of interest were also 
delineated on the post-treatment MRI scan and the catheters 
of 6 patients were reconstructed . The displacement of 
catheters between the MRI scans were analyzed. The intra-
operative dose plan was applied to the post-operative MRI 
scan to assess the influence of catheter migration and 
anatomical variation on the dose delivered to the target and 
the organs at risk. 
Figure 1. A: sagital SPIR image, B: transveral SPAIR image, C-
F: dose differences in CTV and organs at risk between intra-
operative (Intra-op) and post-operative plan (Post-op) 
 
 
Results: In total, the displacements of 87 catheters were 
investigated in the x,y and z direction (Table 1). A 
displacement of 4-5 mm was seen in the z-direction of 2 
catheters. In most catheters, a migration of only 0-2 mm was 
observed. The differences in DVH parameters between the 
intra-operative plan and the post treatment plan are small 
(Figure 1c-f). Intra-operative and post treatment coverage of 
the CTV are comparable (Figure 1c) and dose constraints for 
the organs at risk (D10% urethra 21 Gy, D1cc bladder and 
rectum 12 Gy) were met for almost all cases (Figure 1d-f). 
The D1cc rectum and D1cc bladder were slightly exceeded in 
two cases. In two patients (no. 4 and 6) the D95 of the CTV 
was reduced to prevent large violations in the constraints for 
the organs at risk. 
Table 1: catheter shifts during treatment, post treatment MR 
compared to per operative MR.  
 
 
Conclusions: There is minimal displacement of catheters 
during a single fraction focal MRI guided HDR brachytherapy. 
The differences in dose to the CTV and the organs at risk 
between the intra-operative and post treatment plans are 
small and seem clinically irrelevant. Preliminary results in 
this study show that the intra-operatively planned dose 
resembles the actual delivered dose. 
(1). Pieters BR et al, Radiother Oncol. 2006 Jul;80(1):69-72. 
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Purpose/Objective: In our department, HDR brachytherapy 
as a monotherapy is performed in 4 fractions of 9.5 Gy within 
36 hours for low and intermediate risk prostate cancer (PCa). 
Although the implanted catheters are fixed in a template, 
displacement of catheters does occur between the fractions. 
A simulation study performed in our department showed a 
substantial influence of implant displacement >3 mm on 
organ at risk constraints and target coverage. Therefore, 
displacements >3 mm were corrected. 
We investigated the influence of correction of displaced 
implanted catheters on acute and late toxicity in prostate 
cancer treated by HDR brachytherapy. 
Materials and Methods: Between 2007 and 2013 158 PCa 
patients treated with HDR monotherapy were included. 
The implant displacement was assessed before each fraction 
for every patient according to a set-up protocol using a 
lateral X-ray to check the position of the catheter tips 
relative to the implanted markers. Displacements ≤3 mm 
were not corrected. 
The cumulative gastrointestinal (GI) and genitourinary (GU) 
acute and late toxicities were assessed using both the clinical 
record forms and the self-assessment patients questionnaires. 
Toxicity occurring within 100 days was defined as acute and 
after 100 days as late. 
Significance of difference in acute toxicity between the two 
groups (with and without displacement) was tested using 
Pearson's chi-squared test. Cox regression analysis was 
applied to compare the incidence rate of late toxicity. 
Results: Implant displacement was reported in 72 patients 
(DP). 57 (80%) DP shows one displacement during the 
treatment course, 15 DP (20%) showed more than one 
displacement. DP were divided into 3 groups: implant 
displacement ≤3 mm (4 patients, 5.7%), >3-5 mm (44 patients 
, 61%), >5mm (24 patients, 33.3%). No displacements were 
seen in 86 patients (NDP). 
Acute grade ≥2 GI toxicity was reported in 25.6% NDP and 
30.6% DP (p=0.49). Acute GU toxicity was reported in 36% 
NDP and 44.4% DP (p=0.28).  
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The maximum displacement in mm had no influence on acute 
GI toxicity (p=0.63) nor acute GU toxicity (p=0.73). 
For both acute GI (p=0.36) and GU (p=0.56) toxicity the 
number of displacements was not statistically significant. 
No statistically significant differences were seen in late GI 
toxicity between NDP (9.4%) and DP (8.6%) (p=1.0), while late 
GU toxicity was significantly higher in NDP (30%) versus DP 
(16%) (p=0.04). However, in a multivariate analysis including 
risk factors; age, baseline toxicity, IPSS, Comorbidity, 
number of needles, and prostate volume, the difference in 
late GU between the DP and NDP was not significant anymore 
(P=0.08). 
The influence of maximum displacement was not significant 
for late GI (p=0.71) nor GU (p=0.49) toxicity. 
The number of displacements was also not significantly 
associated with both late GI (p=0.73) and GU (p=0.60) 
toxicity. 
Conclusions: Corrected displacement during the 4 fractions 
regimen of HDR monotherapy did not lead to an increase in 
acute nor late GI and GU toxicity confirming the feasibility of 
our correction protocol to ensure a safe HDR treatment 
regimen. 
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Purpose/Objective: To evaluate the efficacy of CT-guided 
radioactive seed implantation for locally recurrent rectal 
cancer (LRRC) , and analyze the associated prognostic 
factors. 
Materials and Methods: From September 2003 to October 
2014, 97 patients with locally recurrent rectal cancer 
received 125I seeds implantation under CT guidance in our 
center. Each patient underwent three-dimentional treatment 
planning pre-implantation and dosimetric verification post-
implantation. The range of activity of seed was from 0.40 to 
0.8 mCi, and the range of seeds number was from 18 to 137. 
The range of D90 was from 75.91 to 165.27 Gy. Overall 
survival of the patients was calculated and prognostic factors 
were evaluated. 
Results: The follow-up rate was 93.5%, the median follow-up 
time was 15.7 months (4.2 ~ 98.1 months). The response rate 
of pain relief was 95.2%. The overall response rate was 
51.6%, in which complete response rate was16.1% and partial 
response rate was 35.5%. The 1, 2 and 3 year local control 
rates were 32.3%, 11.3% and 11.3%, respectively. The median 
local control time was 8.0 month. The 1, 2 and 3 year 
survival rates were 67.6%, 36.0%and 7.5%, respectively. The 
median overall survival time was 21.5 months. Analysis using 
the Cox proportional hazards model suggested that patients 
with pre-sacral recurrence and patients who received a D90 
higher than 140 Gy may survive for a longer period. 
Conclusions: CT-guided radioactive seed implantation 
provides a safe and effective method to relieve pain, control 
local tumor growth and, to some extent, prolong the survival 
of patients with locally recurrent rectal cancer without 
additional complications. It is an alternative treatment 
option for locally recurrent rectal cancer, especially for 
those with previous pelvic radiation. Location of recurrent 
tumor and accumulated dose may be factors predictive of a 
favorable outcome for patients. These findings need to be 
validated by conducting further studies with larger cohorts.  
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Purpose/Objective: Surface mould brachytherapy (SMB) is a 
century old technique which can be used for various sites 
such as skin, nose, ear and hard palate in the head and neck 
region. There is scarcity of data on high dose rate (HDR) SMB. 
Aim of this study is to evaluate the outcomes of patients 
treated with SMB technique. 
Materials and Methods: Patients with malignant localized 
early T1 or T2, node negative lesions in the head and neck 
region treated with SMB during 2008-2013 were considered. 
Individualized mould was prepared for all patients. Three 
dimensional CT based planning was carried out with the 
mould in situ using the Plato planning system (Nucletron). 
The median number of catheters was 5 (Range 3-7). 
Treatment was delivered using HDR 192 Ir source to a dose 
ranging from 39 to 52.5 Gy (mean 49 Gy) with 350cGy per 
fraction, using bid regimen. Median number of catheters used 
were 5 (range 3 to 7). For the present analysis the data was 
extracted from a prospective brachytherapy database as well 
as from patient charts. The data was analysed using SPSS 
software (V18). Survival analysis was done using Kaplan Meier 
method. 
Results: Thirty one patients were treated with SMB. The 
median age at presentation was 53 years (range 25-82 years). 
Most of the patients were males (n=24). The most common 
site was hard palate in 14 (45%), followed by nose in 7 
(22.5%), soft palate in 5 (16%), tonsil in 2 (6.5%), skin over 
face in 2 (6.5%) and pinna 1 (3.5%). The histology was 
squamous carcinoma in 27 patients, while the rest were basal 
cell carcinoma. The median tumor size was 2 cm. Treatment 
was given in the primary setting in 29 and recurrent setting in 
2 patients. Twenty three patients received the SMB as 
definitive, radical treatment while in 8 it was used as boost 
after external beam radiotherapy. Acute skin toxicity was 
seen in 17 patients of which 10 were grade II reactions. Acute 
mucosal reactions were seen in 19 with grade II in 10 and 
grade III in 1. Median follow up was 29 months (range 4 to 78 
months). Eight patients had recurrent disease (4 primary, 3 
isolated nodal recurrences and 1 primary and nodal 
recurrence). Two patients had died at 4 months and 14 
months. Three year DFS was 70% and 3 year overall survival 
was 91%. Grade 1 mucosal atrophy was seen in 22. Grade 1 
xerostomia was seen in 6 and grade II for 1 patient (all of 
them had received external radiotherapy). On long term 
follow up osteo- necrosis was seen for 2 of which 1 
recurrence had at the primary site. Skin hypopigmentation 
was seen in 3 while telangiectasia was seen in 9 patients. 
Conclusions: Surface mould brachytherapy results in 
acceptable locoregional control rates and good overall 
survival with excellent organ and function preservation.  
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